• ElevationSpace

  Participated · Series B · Sep 2025

  ElevationSpace is developing the ELS-R series re-entry satellites and the ELS-RS high-frequency cargo recovery service to return payloads from orbit to Earth. The company is close to completing assembly of AOBA, its first private re-entry satellite and the inaugural ELS-R model. ElevationSpace leverages Japan’s small-satellite lift-guided re-entry expertise for returning payloads and crew from space. It has pursued global partnerships, including an agreement with Axiom Space and plans to integrate Redwire’s biopharma technology into its platform. Financially, the company has raised $63.5 million in total after securing $40 million in its Series B. Management framed the funding as supporting expansion of domestic and international business and service development under its vision of building an in-orbit transportation network.

• Smart Bank

  Participated · Debt Financing · Apr 2024

  SmartBank provides a finance management app paired with prepaid Visa-branded cards (B/43 My Card, B/43 Pair Card, B/43 Junior Card) and a deposit account that enables payments and P2P transfers. The app targets users in their 20s–30s and couples, and the company reports more than 1 million downloads. SmartBank has obtained a money-transfer license and, in April, a prepaid payment instrument license that allows it to hold user deposits—distinct from peers that cannot hold deposits. It has added product features such as credit-card and bank-account linking and an AI receipt‑reading function using generative AI to act as an AI-driven financial advisor. Revenue today relies largely on interchange fees (IRF), and the company is expanding revenue streams with BNPL, a subscription (B/43 Plus), and referral fees. SmartBank plans to grow headcount (from 49 in October to ~100 by 2025, with half in engineering) and to evolve into a broader bank-like financial platform. SmartBank offers B/43, a combined prepaid card and household budgeting app that reflects spending in real time when users charge monthly budgets to the card. The product includes pair cards for couples and a junior card for parent–child allowance management. Since its April 2021 release the app has reached 1 million cumulative downloads and monthly GMV has expanded to tens of billions of yen. The company reports it has achieved product–market fit with family and couple users and plans to invest in further user growth, product development, and hiring. Financially, SmartBank previously raised ¥3.0 billion in equity and has now completed a ¥1.15 billion debt financing, bringing cumulative funding to ¥4.15 billion. The new funds will be used for working capital for the B/43 business and for growth initiatives.

• Ubie

  Led · Equity · Apr 2024

  Ubie, founded in 2017 and based in New York, offers the Ubie AI Symptom Checker, a medically vetted platform that guides users to appropriate care pathways using predictive models. The company supports over 1,800 provider organizations and leverages disease-prediction AI to help patients navigate healthcare systems. As of June 2025 Ubie has secured over $125 million in cumulative funding. The reported capital will be used to support U.S. expansion, develop generative AI for patient education, and continue refining provider-focused solutions in partnership with the Mayo Clinic. Investors named in the report include Google, JAPAN POST CAPITAL, NTT DOCOMO, SEVEN-ELEVEN JAPAN, Japan Finance Corporation and The Shoko Chukin Bank. Ubie is a healthtech company founded in May 2017 that builds AI-powered products to guide people to appropriate medical care. Its consumer offerings include the symptom search engine Ubie (Japanese and US versions) and Ubie Disease Q&A, together reaching about 10 million monthly users. For healthcare providers it offers Ubie AI Medical Navi, a digital intake and diagnosis-support tool adopted by more than 1,700 medical institutions since its 2018 launch. The company also operates matching businesses that connect consumers and medical providers and has collaborated with pharmaceutical firms, engaging with over two-thirds of global mega‑pharma since its pharma business launch in late 2021. Ubie established a U.S. office in 2022 as part of its international expansion. It plans to use recent funding to grow its pharma-facing business, enhance consumer service features, develop new businesses, and invest in system development and marketing for the Ubie platform. Ubie provides an AI-powered symptom checker app for consumers and a B2B hospital product called Ubie for Hospital (AI Monshin) that automates preliminary patient interviews. AI Monshin selects and asks around 20 questions from 3,500 question types using data extracted from about 50,000 medical research papers. More than 1,100 medical institutions in Japan use AI Monshin, and the consumer app has over 7 million monthly active users. The company employs approximately 200 people. Ubie launched its symptom checker in the U.S. earlier this year, opened a U.S. subsidiary in October, and entered Singapore in August as initial steps toward global expansion. It plans to scale its healthcare platform and ramp up U.S. penetration, while pursuing partnerships with pharmaceutical companies (many based on the U.S. East Coast). Ubie offers an AI-powered patient questionnaire that guides patients from symptoms to appropriate medical care and improves operational efficiency in the medical field. The company is led by CEO Yoshinori Abe. It is building a medical data platform to connect patients, medical institutions, and pharmaceutical companies. Ubie says the platform will help ensure patients visit the right medical institution at the right time and help physicians access relevant, up-to-date knowledge. The company also aims to help pharmaceutical companies provide patients with appropriate information and scientific findings related to their conditions. Ubie intends to use its recent funding to support business growth in Japan and the U.S.

• T2

  Participated · Series A · Sep 2023

  T2 develops and operates autonomous driving trucks for long-distance trunk transportation, currently running commercial operations with its self-developed Level 2 trucks. The company is conducting safety verification using formal methods and has demonstrated roughly 500 km of non-steering driving on highways including toll-booth passages. From 2024 demonstrations, it has transported cargo for over 50 partner companies, and commercial operations that began July 1 last year have expanded to 23 customer companies. T2 plans to deploy Level 4 trunk transportation services from fiscal year 2027 and is building driver-switching hubs called “Transgate” near Ayase, Kobe, and Nishinomiya by spring 2026. Financially, the company has raised over ¥16.5 billion to date, including the ¥5 billion first close of its Series B, and says it will use the new proceeds to accelerate its business and technology development toward Level 4.

• Ball Wave

  Participated · Equity · Mar 2021

  Ball Wave Inc. announced a funding round totaling ¥181,440,000. The transaction closed on March 8, 2021 and was executed via a third‑party allotment of shares. Participating investors included Soshin Kogyo Technology Transfer Co., Ltd., JA Mitsui Leasing, Ltd., Toyoda Gosei Co., Ltd., and Mitsubishi UFJ Capital Co., Ltd. Toyoda Gosei is noted as a returning investor. The articles report the funding amount, participants, and instrument but do not provide additional operational or financial metrics. No other financing terms or use‑of‑proceeds details were disclosed in the articles.

No current team members are available.